

Robert W. Baker, M.D.

Deputy Chief Medical Officer and Vice President, Clinical Program Design, and Vice President, Exploratory Medicine and Pharmacology
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285

Email: baker_robert_w@lilly.com

PRESENT AND PAST LILLY POSITIONS

May 2021 to Present

Deputy Chief Medical Officer, Eli Lilly and Company

January 2021 to Present

Vice President, Exploratory Medicine and Pharmacology, Eli Lilly and Company

January 2018 to Present

Vice President, Exploratory Medicine and Pharmacology, Eli Lilly and Company

November 2020 to April 2021

Vice President, Clinical Development, Eli Lilly and Company

February 2014 – August 2019

Vice President, Global Patient Safety, Eli Lilly and Company

November 2012 – January 2014

Vice President, Global Medical Affairs, Lilly Bio-Medicines Business Unit, Eli Lilly and Company

October 2008 to October 2012

Global Development Leader (Vice President), Psychiatry & Pain Disorders Program, Eli Lilly and Company

November 2006 to March 2008

Group Medical Director, Global Patient Safety, Eli Lilly and Company

April 2005 – October 2006

Medical Director, US Neurosciences, U.S. Medical Division, Eli Lilly and Company

May 2003 – March 2005

Associate Medical Director, US Neurosciences, U.S. Medical Division, Eli Lilly and Company

September 1999 – April 2003

Clinical Research Physician/Senior Clinical Research Physician, Eli Lilly and Company

PAST ROLES: ACADEMIC APPOINTMENTS

1986 – 1988 Clinical Instructor of Psychiatry, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA

1988 – 1996 Assistant Professor of Psychiatry, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA

1997 – 1999 Associate Professor of Psychiatry and Pharmacology, Department of Psychiatry and Human Behavior, University of Mississippi Medical School, Jackson, MS

1999 – 2005 Clinical Associate Professor of Psychiatry (volunteer appointment), Department of Psychiatry and Human Behavior, University of Mississippi Medical School, Jackson, MS

PAST ROLES: WORK ASSIGNMENTS

1986 – 1989 Attending Physician and Admissions Director, Mayview State Hospital, Commonwealth of Pennsylvania, Bridgeville PA

1989 – 1996 Director of Special Studies Center (Schizophrenia Research) at Mayview State Hospital and Attending Psychiatrist Western Psychiatric Institute and Clinic Schizophrenia Inpatient/Outpatient, Geriatric Outpatient and Emergency Psychiatry Divisions, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh PA

1996 EPICS Research Program Medical Director (Psychotherapeutic, Cognitive, and Rehabilitative Research in Schizophrenia: Program Director: Gerard Hogarty), Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA

1997 – 1999 Adult Inpatient Psychiatric Services Director; Residency Training Director; and Clinical Psychopharmacology Research Director, University of Mississippi Medical Center, Jackson, MS

EDUCATION & TRAINING

1989 – 1996 Northwestern University, Evanston, IL (Honors Program in Medical Education), Degree: B.S. in Medical Sciences, 1980, Undergraduate
 1978 – 1982 Northwestern University Medical School, Chicago, IL, Degree: M.D., 1982, Graduate
 1982 – 1983 Intern in Internal Medicine, Montefiore Hospital, University of Pittsburgh School of Medicine, Pittsburgh PA, Post-Graduate
 1983 – 1986 Resident in General Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, PA, Post-Graduate

LICENSURE & CERTIFICATION

1984 Medical Licensure: Commonwealth of Pennsylvania, license # MD-031571-E (inactive)
 1996 Medical Licensure: State of Mississippi, license # 15116
 1983 Certification: National Board of Medical Examiners
 1987 Certification: Psychiatry, certificate # 29352, American Board of Psychiatry and Neurology
 1991 – 2001 Certification: Added Qualifications in Geriatric Psychiatry, certificate # 17, American Board of Psychiatry and Neurology
 1998 – 2008 Certification: Subspecialty in Addiction Psychiatry, certificate # 1445, American Board of Psychiatry and Neurology

SELECTED AWARDS & HONORS

1981 Elected to Alpha Omega Alpha Medical Honor Society)
 1992 Exemplary Psychiatrist Award, National Alliance for the Mentally Ill
 1998 Fellow, American Psychiatric Association
 2004 Distinguished Fellow, American Psychiatric Association

SELECTED SERVICE (NON-LILLY)

1998 – 1999 Associate Editor, The Journal of Psychotic Disorders: Reviews and Commentaries
 1988 – 2004 Examiner, Part II Psychiatry Certification Exam, American Board of Psychiatry and Neurology
 1999 Member, Psychiatry Minor Committee for Part I Certification Exam, American Board of Psychiatry and Neurology
 1997 – 2001 Assembly Representative from the Mississippi Psychiatric Association, American Psychiatric Association
 1999 – 1999 Executive Council, Mississippi Psychiatric Association
 1999 – 2001 Member, Psychiatry Recertification Examination Committee, American Board of Psychiatry and Neurology
 1999 – 2005 Member, Scientific Program Committee, American Psychiatric Association
 1999 – 2005 Member, Symposia Subcommittee, Scientific Program Committee, American Psychiatric Association
 2014 Member, Clinical and Preclinical Development Committee, Pharmaceutical Research and Manufacturers of America
 2015 – 2016 Clinical Chair, Clinical and Preclinical Development Committee, Pharmaceutical Research and Manufacturers of America
 2017 – 2019 Workstream Leader, Interpretation of Pharmacovigilance Guidance and Regulations and member, Pharmacovigilance Steering Committee, TransCelerate Biopharma Inc.
 2019 - Present Corporate Secretary, TransCelerate Biopharma Inc.
 2020 - Present Industry representative, Psychopharmacological Drugs Advisory Committee, Food and Drug Administration
 2020 - Present Clinical Trial Diversity Leadership Committee, Pharmaceutical Research and Manufacturers of America

MEMBERSHIPS IN PROFESSIONAL SOCIETIES

1979 – 1982 American Medical Student Association
 1986 – 2012 American Psychiatric Association
 1986 – 1996 Pennsylvania Psychiatric Association
 1997 – 2005 Mississippi Psychiatric Association
 2005 – 2012 Indiana Psychiatric Society
 1998 – 1999 American Association of Directors of Psychiatry Residency Training

PUBLICATIONS & PUBLISHED PEER-REVIEWED MANUSCRIPTS

1. Zipursky RB, Baker RW, Zimmer B: Alprazolam withdrawal delirium unresponsive to diazepam: Case report. J Clin Psychiatry 46:344-5, 1985.

2. Conley RR, Schulz SC, Baker RW, Collins JF, Bell JA: Clozapine efficacy in schizophrenic nonresponders. *Psychopharmacol Bull* 24: 269-74, 1988.
3. Trzepacz PT, Baker RW, Greenhouse J: A symptom rating scale for delirium. *Psychiatry Res* 23:89-97, 1988.
4. Conley RR, Baker RW: Family response to improvement by a relative with schizophrenia. *Hosp and Community Psych* 41:989-901, 1990.
5. Birmaher B, Baker R, Kapur S, Quintana H, Ganguli R: Clozapine for the treatment of adolescents with schizophrenia. *J American Academy of Child and Adolescent Psychiatry* 31:160-164, 1992.
6. Baker RW, Chengappa KNR, Baird JW, Steingard S, Schooler N, Christ MA: Emergence of obsessive-compulsive symptoms during treatment with clozapine. *J Clin Psychiatry* 53:439-442, 1992.
7. Chengappa KNR, Shelton MD, Baker RW, Schooler NR, Baird J, Delaney J: The prevalence of akathisia in patients receiving stable doses of clozapine. *J Clin Psychiatry* 55:142-145, 1994.
8. Chengappa KNR, Baker RW, Kreinbrook SB, Adair D: Clozapine use in female geriatric patients with psychoses. *J Geriatric Psychiatry* 8: 12-15, 1995.
9. Chengappa KNR, Baker RW, Sirri C: The successful use of clozapine in ameliorating self mutilation in a patient with borderline personality disorder. *J Personality Disorders*, 9:76-82, 1995.
10. Chengappa KNR, Baker R, Pelucio M, Cole D: Recurrent pancreatitis on clozapine rechallenge. *J Psychopharmacology*, 9: 367-368, 1995.
11. John JP, Chengappa KNR, Baker RW, Gupta B, Mortimer MT: Assessment of changes in both weight and frequency of use of medications for the treatment of gastrointestinal symptoms among clozapine-treated patients. *Ann Clin Psychiatry*, 7: 119-125, 1995.
12. Baker RW, Ames D, Umbricht DSG, Chengappa KNR, Schooler NR: Obsessive-compulsive symptoms in schizophrenia: A comparison of olanzapine and placebo. *Psychopharmacol Bull*, 32: 89-93, 1996.
13. Chengappa KNR, Gopalani A, Haught MK, McChesney K, Baker RW, Schooler NR: The treatment of clozapine-associated agranulocytosis with granulocyte colony-stimulating factor (G-CSF). *Psychopharmacol Bull*, 32: 111-121, 1996.
14. Ames D, Wirshing WC, Baker RW, Umbricht DSG, Sun AB, Carter J, Schooler NR, Kan JM, Marder SR: Predictive value of eosinophilia for neutropenia during clozapine treatment. *J Clin Psychiatry* 57: 579-581, 1996.
15. Baker RW, Bermanzohn PC, Wirshing DA, Chengappa KNR: Obsessions, compulsions, clozapine, and risperidone. *CNS Spectrums* 2: 26-36, 1997.
16. Thompson J, Chengappa KNR, Good CB, Baker RW, Kiewe RP, Bezner J, Schooler NR: Hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria, and proteinuria occurring early in clozapine treatment. *International Clinical Psychopharmacology* 13: 95-98, 1998.
17. Sanders RD, Forman SD, Pierri JN, Baker RW, Kelley ME, Van Kammen DP, Keshavan MS. Inter-rater reliability of the neurological examination in schizophrenia. *Schizophrenia Research* 29: 287-292, 1998
18. Ahmed S, Chengappa KNR, Naidu VR, Baker RW, Parepally H, Schooler NR: Clozapine withdrawal-emergent dystonias and dyskinesias: a case series. *J Clin Psychiatry*, 59: 472-477, 1998
19. Chengappa KNR, Sheth S, Brar JS, Parepally H, Marcus S, Gopalani A, Palmer A, Baker RW, Schooler NR: Risperidone use at a state hospital: A clinical audit 2 years after the first wave of risperidone prescriptions. *J Clin Psychiatry*, 60: 373-378, 1999

20. Rush CR, Baker RW, Wright K: Acute physiological and behavioral effects of oral cocaine in humans: A dose-response analysis. *Drug and Alcohol Dependence*, 55: 1-12, 1999
21. Rush CR, Baker RW, Wright K: Trazodone, zolpidem, and triazolam in humans: Acute behavioral effects and abuse potential. *Psychopharmacology*, 144: 220-233, 1999
22. Rush CR, Baker RW, Rowlett JK: Discriminative-stimulus effects of zolpidem, triazolam, pentobarbital, and caffeine in zolpidem-trained humans. *Experimental & Clinical Psychopharmacology*, 8:22-36, 2000
23. Rush CR, Baker RW: Zolpidem and triazolam interact differentially with a delay interval on a digit-enter-and-recall task. *Hum Psychopharmacol Clin Exp*, 16: 147-157, 2001
24. Rush CR, Essman WD, Simpson CA, Baker RW: Reinforcing and subject-rated effects of methylphenidate and d-amphetamine in non-drug-abusing humans. *Journal of Clinical Psychopharmacology*, 21: 273-86, 2001
25. Kane JM, Marder SM, Schooler NR, Wirshing WC, Umbricht D, Baker RW, Wirshing DA, Safferman A, Ganguli R, McMeniman M, Borenstein M: Clozapine and haloperidol in moderately refractory schizophrenia: a six-month randomized double blind comparison. *Arch Gen Psychiatry* 58: 965-72, 2001.
26. Rush CR, Baker RW: Behavioural pharmacological similarities between methylphenidate and cocaine in cocaine abusers. *Experimental and Clinical Psychopharmacology*, 9: 59-73, 2001.
27. Kennedy JS, Bymaster FP, Schuh L, Calligaro DO, Nomikos G, Felder CC, Bernauer M, Kinon BJ, Baker RW, Hay D, Roth HJ, Dossenbach M, Kaiser C, Beasley CM, Holcombe JH, Effron MB, Breier A: A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data. *International Journal of Geriatric Psychiatry*, 16: S33-61, 2001.
28. Chengappa KN, Vasile J, Levine J, Ulrich R, Baker R, Gopalani A, Schooler R: Clozapine: its impact on aggressive behavior among patients at a state psychiatric hospital. *Schizophrenia Research*, 53:1-6, 2002.
29. Tohen M, Chengappa KNR, Suppes TR, Zarate CA, Calabrese JR, Bowden CL, Sachs GS, Kupfer DJ, Baker RW, Risser RC, Keeter EL, Feldman PD, Tollefson GD, Breier A: Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. *Arch Gen Psychiatry*, 59: 62-69, 2002.
30. Baker RW, Goldberg JF, Tohen M, Milton DR, Stauffer VL, Schuh LM: The impact of response to previous mood stabilizer therapy on response to olanzapine versus placebo for acute mania. *Bipolar Disorders* 4(1), 43-49, 2002.
31. Tohen M, Baker RW, Altshuler L, Zarate CA, Suppes T, Ketter TA, Milton DR, Risser R, Gilmore JA, Breier A, Tollefson GA: Olanzapine versus divalproex in the treatment of acute mania. [erratum appears in *Am J Psychiatry*. 2005 Feb;7(1):102] *Am J Psychiatry* 159(6): 1011-1017, 2002.
32. Rush CR, Kelly TH, Hays LR, Baker RW, Wooten AF. Acute behavioral and physiological effects of modafinil in drug abusers. *Behavioral Pharmacology* 13(2) 105-112, 2002.
33. Baker RW, Milton DR, Stauffer VL, Gelenberg A, Tohen M: Placebo-controlled trials do not find association of olanzapine with exacerbation of bipolar mania. *J Affective Dis* 73: 147-53, 2003.
34. Chengappa KNR, Baker RW, Shao L, Yatham LN, Tohen M, Gershon S, Kupfer D: Rates of response, euthymia, and remission in two placebo-controlled olanzapine trials for bipolar mania. *Bipolar Disorders* 5:1-5, 2003.

35. Baker RW, Tohen M, Swann AC, Fawcett J, Risser RC, Schuh LM, Stauffer VL, Tollefson GD: Acute dysphoric mania: treatment response to olanzapine versus placebo. *J Clin Psychopharmacol* 23: 132-7, 2003.
36. Tohen M, Ketter TA, Zarate CA, Suppes T, Frye M, Altshuler L, Zajecka J, Schuh LM, Risser RC, Brown E, Baker RW. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. *Am J Psychiatry*, 160: 1263-1271, 2003.
37. Baker RW, Kinon BJ, Maguire GA, Liu H, Hill AL. Effectiveness of rapid initial dose escalation of up to 40 mg per day oral olanzapine in acute agitation. *Journal Clinical Psychopharmacol* 23: 342-348, 2003.
38. Baldessarini RJ, Hennen J, Wilson M, Calabrese J, Chengappa R, Keck PE Jr, McElroy SL, Sachs G, Vieta E, Welge JA, Yatham LN, Zarate CA Jr, Baker RW, Tohen M. Olanzapine vs. placebo in acute mania: treatment responses in subgroups. *J Clinical Psychopharmacology* 23: 370-376, 2003.
39. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dubé S, Tollefson GD, Breier A. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression [erratum appears in *Arch Gen Psychiatry*. 2004 Feb;61(2):176]. *Arch Gen Psychiatry*, 60: 1079-1088, 2003.
40. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, Azorin JM, Vieta E, Hardy-Bayle M-C, Lawson WB, Emsley RA, Zhang F, Baker RW, Risser RC, Namjoshi MA, Evans AR, Breier A: A 12-week double-blind comparison of olanzapine versus haloperidol in the treatment of acute mania. *Archives Gen Psychiatry*, 60: 1218-1226, 2003.
41. Haga JL, Baker RW, Rush CR. Behavioral and physiological effects of cocaine in humans following triazolam. *Pharmacology, Biochemistry & Behavior*. 76(3-4):383-92, 2003.
42. Shi L, Namjoshi MA, Swindle R, Yu X, Risser R, Baker RW, Tohen M. Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: A secondary analysis of a double-blind, placebo-controlled, randomized clinical trial. *Clinical Therapeutics*, 26:125-134, 2004.
43. Tohen M, Chengappa KNR, Suppes T, Baker RW, Zarate CA, Bowden C, Sachs GS, Kupfer DJ, Ghaemi SN, Feldman PD, Risser RC, Evans AR, Calabrese JR. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. *British Journal of Psychiatry*. 184:337-45, 2004.
44. Lindenmayer JP, Brown E, Baker RW, Schuh LM, Shao L, Tohen M, Ahmed S, Stauffer VL. An excitement subscale of the Positive and Negative Syndrome Scale. *Schizophrenia Research*. 68(2-3):331-7, 2004.
45. Kinon BJ, Liu-Seifert H, Ahl J, Ahmed S, Baker RW. Longitudinal effect of olanzapine on fasting serum lipids: a randomized, prospective, 4-month study. *Annals of the New York Academy of Sciences*. 1032:295-6, 2004.
46. Baker RW, Brown E, Akiskal HS, Calabrese JR, Ketter TA, Schuh LM, Trzepacz PT, Watkin JG, Tohen M. Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania. *British Journal of Psychiatry*. 185:472-8, 2004
47. Chengappa KNR, Hennen J, Baldessarini RJ, Kupfer D, Yatham LN, Gershon S, Baker RW, Tohen M. Recovery and functional outcomes following olanzapine treatment for bipolar I mania. *Bipolar Disorders*. 7(1):68-76, 2005.
48. Zhu B, Tunis S, Zhao Z, Baker RW, Lage MJ, Shi L, Tohen M. Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trial. *Current Medical Research & Opinion*. 21(4):555-64, 2005.
49. Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, Koukopoulos A, Cassano GB, Grunze H, Licht RW, Dell'Osso L, Evans AR, Risser R, Baker RW, Crane H, Dossenbach MR, Bowden CL. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. *American Journal of Psychiatry*. 162(7):1281-90, 2005.
50. Suppes T, Brown E, Schuh LM, Baker RW, Tohen M. Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: post hoc analyses of 47-week data. *Journal of Affective Disorders*. 89(1-3):69-77, 2005.
51. Kennedy J, Deberdt W, Siegal A, Micca J, Degenhardt E, Ahl J, Meyers A, Kaiser C, Baker RW. Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia. *International Journal of Geriatric Psychiatry*. 20(11):1020-7, 2005.

52. Micca J, Hoffmann VP, Lipkovich I, Ahl J, Baker RW, Hardy TA. Retrospective analysis of diabetes risk in elderly patients with dementia in olanzapine clinical trials. *American Journal of Geriatric Psychiatry*. 14(1):62-70, 2006.
53. Tohen M, Calabrese JR, Sachs GS, Banov MD, Detke HC, Risser R, Baker RW, Chou JC, Bowden CL. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. *American Journal of Psychiatry*. 163(2):247-56, 2006.
54. Perlis RH, Brown E, Baker RW, Nierenberg AA. Clinical features of bipolar depression versus major depressive disorder in large multicenter trials. *American Journal of Psychiatry*. 163(2):225-31, 2006.
55. Williamson D, Brown E, Perlis RH, Ahl J, Baker RW, Tohen M. Clinical relevance of depressive symptom improvement in bipolar I depressed patients. *Journal of Affective Disorders*. 92(2-3):261-6, 2006.
56. Perlis RH, Baker RW, Zarate CA Jr., Brown EB, Schuh LM, Jamal HH, Tohen M. Olanzapine versus risperidone in the treatment of manic or mixed states in bipolar I disorder: A randomized, double-blind trial. *Journal of Clinical Psychiatry*. 67 (11): 1747-53, 2006.
57. Houston JP, Lipkovich IA, Ahl J, Rotelli MD, Baker RW, Bowden CL. Initial symptoms of manic relapse in manic or mixed-manic bipolar disorder: post hoc analysis of patients treated with olanzapine or lithium. *Journal of Psychiatric Research*. 41(7):616-21, 2007.
58. Tamayo JM, Mazzotti G, Tohen M, Gattez WF, Zapata R, Castillo JJ, Fahrer RD, Gonzales-Pinto AM, Vieta E, Azorin JM, Brown E, Brunner E, Rovner J, Bonnett-Perrin E, Baker RW. Outcomes for Latin American versus White patients suffering from acute mania in a randomized, double-blind trial comparing olanzapine and haloperidol. *Journal of Clinical Psychopharmacology*. 27(2): 126-34, 2007.
59. Piletz J, Baker R, Halaris A. Platelet imidazoline receptors as a state marker for depressive symptomatology. *Journal of Psychiatric Research*. 42 (1); 41-9, 2008.
60. Ascher-Svanum H, Nyhuis AW, Faries DE, Kinon BJ, Baker RW, Shekhar A. Clinical, functional, and economic ramifications of early non-response to antipsychotics in the naturalistic treatment of schizophrenia. *Schizophrenia Bulletin*. 34(6) 1163-71, 2008.
61. Spann M, Lindborg S, Seaman J, Baker R, Dunayevich E, Breier A. Bayesian adaptive non-inferiority with safety assessment: Retrospective case study to highlight potential benefits and limitations of the approach. *Journal of Psychiatric Research*, 2009 Feb;43(5):561-7. doi:10.1016/j.jpsychires.2008.07.009. Epub 2008 Sep 18.
62. Marder SR, Sorsaburu S, Dunayevich E, Karagianis JL, Dawe IC, Falk DM, Dellva MA, Carlson JL, Cavazzoni PA, Baker RW. Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation. *J Clin Psychiatry*, 71(4):433-41, 2010.
63. Schooler NR, Marder SR, Chengappa KN, Petrides G, Ames D, Wirshing WC, McMeniman M, Baker RW, Parepally H, Umbricht D, Kane JM. Clozapine and risperidone in moderately refractory schizophrenia: a 6-month randomized double-blind comparison. *J Clin Psychiatry*,77(5):628-34

PUBLISHED PEER-REVIEWED LETTERS

1. Baker RW, Conley RR: Seizures during clozapine therapy. *Am J Psychiatry* 148:1265-1266, 1991.
2. Baker RW: Fluoxetine and schizophrenia in a patient with obsessional thinking. *Journal of Neuropsychiatry* 4:232-3, 1992.
3. Steingard S, Chengappa KNR, Baker RW, Schooler NR: Clozapine, obsessive symptoms, and serotonergic mechanisms. *Am J Psychiatry* 150:1435, 1993.
4. Chengappa KNR, Baker RW, Baird J: Iron for chronic and persistent akathisia? *J Clin Psychiatry* 54:320-321, 1993.
5. Chengappa KNR, Baker RW, Harty I: Seizures and clozapine dosing schedule. *J Clin Psychiatry* 55: 456, 1994.
6. Baker RW, Chengappa KNR: Further study of Neuroleptic Malignant Syndrome. *Am J Psychiatry* 152: 1831, 1995.
7. Baker RW: Possible dose-response relationship for risperidone in obsessive-compulsive disorder. *J Clin Psychiatry* 59: 134, 1998.

8. Baker RW, Chengappa KNR: Clozapine and gastro-esophageal reflux. *J Clin Psychiatry* 59: 257, 1998.

9. Singh, A; Twomey K; Baker R: Global pharmacovigilance regulations: Call for re-harmonization. *Clinical Trials* 15: 631-32, 2018.

NON-PEER-REVIEWED PUBLICATIONS:

Books:

Trzepacz PT, Baker RW, The Psychiatric Mental Status Examination, Oxford University Press, 202 pp., New York, 1993.

Also published as Portuguese Translation: Trzepacz PT, Baker RW, Exame Psiquiátrico do Estado Mental. Climepsi Editores, Lisbon, Portugal, 2001.

Chapters:

1. Schulz SC, Kahn EM, Baker RW, Conley RR: Lithium and carbamazepine augmentation in treatment refractory schizophrenia. Chapter in The Neuroleptic Nonresponsive Patients: Characterization and Treatment: Angrist, B and Schulz SC. (Eds), pp. 109-136. American Psychiatric Press, Washington, 1990.

2a. Baker RW, Trzepacz PT. Mental status examination. Chapter in The Psychologist's Desk Reference: Koocher G (ed.), pp. 6-11. Oxford University Press, New York, 1998.

2b. Baker RW, Trzepacz PT. Mental status examination. Chapter in The Psychologist's Desk Reference, second edition: Koocher GP, Norcross JC, Hill SS III (eds.), pp. 7-12. Oxford University Press, New York, 2005.

3. Schooler N, Baker R. Providing quality care in the context of clinical research. Chapter in Ethics in Psychiatric Research: A Resource Manual for Human Subjects Protection. Pincus HA, Lieberman JA, Ferris S (eds.), pp. 61-80. American Psychiatric Press, Inc., Washington, 1999.

4. Baker RW, Schuh LM, Tohen M: The use of atypical antipsychotic agents in the treatment of diagnostic subgroups of bipolar disorder: mixed and pure states, psychotic and non-psychotic. Chapter in Bipolar Disorders: Mixed States, Rapid Cycling and Atypical Forms. Marneros A, Goodwin F (eds.), pp. 353-368. Cambridge University Press, Cambridge, 2005.

Other:

1. Baker RW, Chengappa KNR, Steingard S, Schooler NR, Baird JW: More on obsessive-compulsive symptoms and clozapine (reply to letter to the editor). J Clin Psychiatry 55:312, 1994.

2. Hogarty GE, Schooler NR, Baker RW: Taking issue: Efficacy versus effectiveness. (editorial) Psychiatric Services 48: 1107, 1997.

3. Clewell JD, Baker RW. Comments to the editor on "Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model". Value in Health. 8(2):175-6, 2005

